Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

BIZARRE: Sorrento s scilex unit begins mid stage study of lower back pain drug | Mind Blowing Facts

Scilex Holding Company, a Sorrento Company (NASDAQ:SRNE) announced dosing of the first patient in a Phase 2 study of its drug candidate in patients with SP-103 in subjects with acute low back pain (LBP).

The Phase 2, multi center study evaluates the safety and efficacy of SP-103 in patients suffering from acute LBP, with a goal to enrol 80 patients.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.